SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration showing hands removing pieces of pie chart
Job Trends
Adapting in Uncertain Times: Biopharma Professionals Turn To Fractional Roles
1 in 5 respondents either have had or do have a fractional role, according to a recent BioSpace poll, and over half are considering it. Two recruitment experts, a fractional worker and an aspiring fractional worker share their insights.
July 17, 2025
 · 
6 min read
 · 
Angela Gabriel
L-R: Deb Bellina, Mitze Klingenberg, Nicole Cimbura, Lorri Cavalierre, Kandy Simons, Rebecca Andrews
ALS
Patients Fight for Access to BrainStorm’s ALS Drug After Expanded Access Data ‘Defy Logic’
Participants in trials of BrainStorm Cell Therapeutics’ NurOwn filed a Citizens’ Petition with the FDA earlier this month seeking a new review of the stem cell therapy that was rejected in 2022 based on real-world data and 90% survival in an expanded access program.
July 17, 2025
 · 
9 min read
 · 
Heather McKenzie
Layoffs
Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta Therapeutics adds a black box warning to the gene therapy for acute liver injury and failure and parts with more than a third of employees.
July 16, 2025
 · 
2 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
With venture funding tightening in the post-COVID landscape, efficiency has become more critical than ever. In this interactive webinar industry experts explored actionable strategies for maintaining quality under financial pressure. Watch now.
July 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Goal disorientation and lack of vision. Inability to set the right business objectives. Failure to achieve the objectives. Missing the unrealistic and inaccurate company goals.
Rare diseases
AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials
The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an unspecified patient subgroup.
July 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Johnson & Johnson's business center in Switzerland
Earnings
J&J Targets $50B Oncology Sales By 2030: Updated
Johnson & Johnson’s $23.7 billion in second-quarter earnings, driven by cancer and neuroscience drugs, exceeded analyst expectations, while CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030.
July 16, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Adult hand intends to puncture a balloon held by a girl. Child neglect and suppression dreams and wishes of kid. Parental control and authoritarian nurturing. Psychological abuse and domestic violence
Antibody-drug conjugate
GSK’s Blenrep DREAMMs Turn Fitful as FDA Questions Comeback in Multiple Myeloma
In advance of this week’s adcomm, the FDA flags ocular toxicities associated with the antibody-drug conjugate, which received accelerated approval in August 2020 but was pulled from the market two years later after a confirmatory trial failed to improve progression-free survival.
July 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
Shanghai-based LaNova Medicines—which has captured the attention of some of the biggest Western pharmas—will be folded into fellow Chinese company Sino Biopharmaceutical in a deal worth up to $951 million.
July 16, 2025
 · 
1 min read
 · 
Tristan Manalac
COVID-19
Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids
In a July 9 memo, the director of the FDA’s Center for Biologics Evaluation and Research contended there was not enough evidence that the benefits of Moderna’s COVID-19 vaccine Spikevax outweighed its risks in healthy children.
July 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS